Dapagliflozin, an SGLT2 inhibitor, for diabetes
- PMID: 20609956
- DOI: 10.1016/S0140-6736(10)60749-0
Dapagliflozin, an SGLT2 inhibitor, for diabetes
Comment on
-
Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial.Lancet. 2010 Jun 26;375(9733):2223-33. doi: 10.1016/S0140-6736(10)60407-2. Lancet. 2010. PMID: 20609968 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
